DK0497915T3 - hPTH fragment (1-37), its preparation, drug containing it, and its use - Google Patents
hPTH fragment (1-37), its preparation, drug containing it, and its useInfo
- Publication number
- DK0497915T3 DK0497915T3 DK90917747.9T DK90917747T DK0497915T3 DK 0497915 T3 DK0497915 T3 DK 0497915T3 DK 90917747 T DK90917747 T DK 90917747T DK 0497915 T3 DK0497915 T3 DK 0497915T3
- Authority
- DK
- Denmark
- Prior art keywords
- hpth
- fragment
- peptide
- existence
- fragments
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 230000004071 biological effect Effects 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 1
- 102000003982 Parathyroid hormone Human genes 0.000 abstract 1
- 108010049264 Teriparatide Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 238000003795 desorption Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000000260 male genitalia Anatomy 0.000 abstract 1
- 238000004949 mass spectrometry Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000849 parathyroid Effects 0.000 abstract 1
- 239000000199 parathyroid hormone Substances 0.000 abstract 1
- 108010073230 parathyroid hormone (1-38) Proteins 0.000 abstract 1
- 239000013558 reference substance Substances 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
A human blood peptide, hPTH (1-37), the structure of which has been elucidated, can be used as a drug for diagnostic, medical and industrial purposes. The isolation of an hPTH (38-84) fragment demonstrates the existence of the hPTH (1-37). Removal of amino-terminal amino acids on the hPTH (1-37) reduces its biological activity. The hPTH (1-37) which circulates in the blood is identical to the synthetic reference substance hPTH (1-37), but not fragments such as hPTH (1-33), hPTH (1-34) or hPTH (1-38). The existence of the hPTH (1-37) molecular form was proved by mass spectroscopy (plasma desorption method). A different biological activity and differences in the three-dimensional peptide structure between the hPTH (1-37) fragment and other hPTH fragments prove that this hPTH fragment is the preferred natural peptide of the parathormone family, which should be used for treating diseases of the parathyroids, the circulatory and respiratory systems, the male genital organ and the kidneys.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3935738A DE3935738A1 (en) | 1989-10-27 | 1989-10-27 | DRUGS CONTAINING THE HUMAN PARATHORMONE FRAGMENT (1-37) AS AN ACTIVE AGENT |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0497915T3 true DK0497915T3 (en) | 1995-09-25 |
Family
ID=6392300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK90917747.9T DK0497915T3 (en) | 1989-10-27 | 1990-10-25 | hPTH fragment (1-37), its preparation, drug containing it, and its use |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0497915B1 (en) |
| JP (1) | JP3135122B2 (en) |
| AT (1) | ATE121424T1 (en) |
| AU (1) | AU643725B2 (en) |
| CA (1) | CA2071538C (en) |
| DE (2) | DE3935738A1 (en) |
| DK (1) | DK0497915T3 (en) |
| ES (1) | ES2071837T3 (en) |
| GR (1) | GR3015909T3 (en) |
| WO (1) | WO1991006564A1 (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4039656A1 (en) * | 1990-12-12 | 1992-06-17 | Bissendorf Peptide Gmbh | DRUGS, CONTAINING THE HUMAN PARATHORMONE FRAGMENT (1-37) IN THE FORM OF AMIDE OR ETHYLAMIDE AS AN ACTIVE AGENT |
| RU2112515C1 (en) * | 1991-12-17 | 1998-06-10 | Проктер энд Гэмбл Фармасьютикалз, Инк. | Method of osteoporosis treatment |
| DE4203040A1 (en) * | 1992-02-04 | 1993-08-05 | Boehringer Mannheim Gmbh | NEW PARATHORMON FRAGMENTS, THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM |
| US5496801A (en) * | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
| DE4434551A1 (en) * | 1994-09-28 | 1996-04-04 | Forssmann Wolf Georg Prof Dr D | Peptides from the sequence of hPTH (1-37) |
| DE19517430A1 (en) * | 1995-05-12 | 1996-11-14 | Boehringer Mannheim Gmbh | Pharmaceutical dosage form of parathyroid hormone with a two to six hour drug release period |
| EP0861325A1 (en) * | 1995-11-16 | 1998-09-02 | Boehringer Mannheim Gmbh | Process for the preparation of peptides by way of streptavidin fusion proteins |
| SE9702401D0 (en) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| PL195703B1 (en) * | 1997-09-09 | 2007-10-31 | Hoffmann La Roche | Treatment of bone fractures involving the use of pthrp analogues |
| US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
| ZA9811127B (en) * | 1997-12-09 | 2000-07-11 | Lilly Co Eli | Stabilized teriparatide solutions. |
| SE9801495D0 (en) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulation |
| DZ2873A1 (en) | 1998-08-19 | 2003-12-15 | Lilly Co Eli | Method for increasing bone hardness and stiffness. |
| US20040033950A1 (en) | 2000-09-26 | 2004-02-19 | Hock Janet M. | Method of increasing bone toughness and stiffness and reducing fractures |
| US7820393B2 (en) | 1999-01-14 | 2010-10-26 | Scantibodies Laboratory, Inc. | Methods, kits and antibodies for detecting parathyroid hormone |
| US6689566B1 (en) | 1999-01-14 | 2004-02-10 | Scantibodies Laboratory, Inc. | Methods, kits, and antibodies for detecting parathyroid hormone |
| US6923968B2 (en) | 2000-08-10 | 2005-08-02 | Scantibodies Laboratory, Inc. | Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis |
| WO2004028444A2 (en) | 1999-06-02 | 2004-04-08 | Scantibodies Laboratory, Inc. | Parathyroid hormone antagonists and uses thereof |
| US6524788B1 (en) | 2001-11-02 | 2003-02-25 | Thomas L. Cantor | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| US7056655B2 (en) | 2001-11-02 | 2006-06-06 | Scantibodies Laboratory, Inc. | Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism |
| JP6046862B2 (en) * | 2013-08-21 | 2016-12-21 | カディラ ヘルスケア リミテッド | Purification method of PTH |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3243358A1 (en) * | 1982-11-24 | 1984-05-24 | Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch | SYNTHETIC HUMANES (1-38) PARATHORMONE FRAGMENT, METHOD FOR THE PRODUCTION THEREOF AND THE USE FOR TREATING THE OSTEOPOROSIS |
| US4771124A (en) * | 1987-05-26 | 1988-09-13 | Merck & Co., Inc. | Parathyroid hormone antagonists with simplified synthetic methodology |
-
1989
- 1989-10-27 DE DE3935738A patent/DE3935738A1/en not_active Withdrawn
-
1990
- 1990-10-25 JP JP03500084A patent/JP3135122B2/en not_active Expired - Fee Related
- 1990-10-25 ES ES90917747T patent/ES2071837T3/en not_active Expired - Lifetime
- 1990-10-25 DK DK90917747.9T patent/DK0497915T3/en active
- 1990-10-25 CA CA002071538A patent/CA2071538C/en not_active Expired - Fee Related
- 1990-10-25 AT AT90917747T patent/ATE121424T1/en not_active IP Right Cessation
- 1990-10-25 DE DE59008949T patent/DE59008949D1/en not_active Expired - Fee Related
- 1990-10-25 AU AU68712/91A patent/AU643725B2/en not_active Ceased
- 1990-10-25 WO PCT/EP1990/001807 patent/WO1991006564A1/en active IP Right Grant
- 1990-10-25 EP EP90917747A patent/EP0497915B1/en not_active Expired - Lifetime
-
1995
- 1995-04-20 GR GR950401002T patent/GR3015909T3/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0497915B1 (en) | 1995-04-19 |
| GR3015909T3 (en) | 1995-07-31 |
| AU643725B2 (en) | 1993-11-25 |
| JPH05505594A (en) | 1993-08-19 |
| ES2071837T3 (en) | 1995-07-01 |
| WO1991006564A1 (en) | 1991-05-16 |
| EP0497915A1 (en) | 1992-08-12 |
| DE59008949D1 (en) | 1995-05-24 |
| AU6871291A (en) | 1991-05-31 |
| DE3935738A1 (en) | 1991-05-08 |
| JP3135122B2 (en) | 2001-02-13 |
| ATE121424T1 (en) | 1995-05-15 |
| CA2071538C (en) | 2000-09-19 |
| CA2071538A1 (en) | 1991-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0497915T3 (en) | hPTH fragment (1-37), its preparation, drug containing it, and its use | |
| RU2224539C2 (en) | TREATING FRACTURES WITH THE HELP OF ANALOGS OF PEPTIDE BEING ANALOGOUS TO PARATHYROID HORMONE (PTHrP) | |
| DE3587941D1 (en) | DEVICE FOR PROVISIONAL REPERFUSION TREATMENT OF HEART ATTACK SYMPTOMS. | |
| GB2108388A (en) | Composition and method for treating alcohol and drug addicts | |
| EP0526544A4 (en) | Therapeutic uses of actin-binding compounds | |
| ATE204178T1 (en) | METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN | |
| ATE73663T1 (en) | PHOSPHONYLMETHOXYALKYL-ADENINES FOR THE TREATMENT OF VIRUS DISEASES. | |
| DE69032484D1 (en) | COMPOSITIONS AND THE USE THEREOF TO PROMOTE IMMUNOPOTENTIATION | |
| GR1001065B (en) | Polypeptide analogs of apolipoprotein e diagnostic systems and methods using the analogs | |
| ATE132757T1 (en) | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF PROLONGED CLOTTING TIME | |
| DK610888D0 (en) | CARDIODILATE INGREDIENT, METHOD OF PREPARING THEREOF AND ITS USE | |
| LIAN et al. | In vitro degradation of bone particles by human monocytes is decreased with the depletion of the vitamin K-dependent bone protein from the matrix | |
| Mason et al. | Blood concentrations of dihydroxylated vitamin D metabolites after an oral dose. | |
| GREGERSEN | Postpartum haemolytic-uraemic syndrome successfully treated with antithrombin III | |
| DK325289D0 (en) | STRONTIUM SALT, METHOD OF PREPARING IT, AND PHARMACEUTICAL AGENTS CONTAINING SALT | |
| ATE115863T1 (en) | USE OF A PREPARATION CONTAINING IMMUNOLOBULIN FOR THE PROPHYLAXIS AND THERAPY OF AIDS IN HUMAN BEINGS. | |
| NO890174L (en) | RECOMBINANT INTERLEUKIN-1ALFA POLYPEPTIDES. | |
| Biggs et al. | Prolonged Q fever associated with inappropriate secretion of anti-diuretic hormone | |
| Pennell et al. | Isolation of properdin from human plasma. | |
| Gordan | A direct action of parathyroid hormone on dead bone in vitro | |
| HUT41632A (en) | Process for preparing agents for the enhancement of protein absorption | |
| Kotkes et al. | New approaches to the characterization and isolation of migration inhibitory factor (MIF) | |
| ES2052267T3 (en) | ANTI-RH (D) MODIFIED HUMAN ANTIBODIES. | |
| JPS6490127A (en) | Method for remedying malignant tumor or such and composition for remedying same | |
| ES2015772A6 (en) | Process for obtaining new 5-fluorouracil derivatives, specifically N1-acyl-substituted-N3-orthotoluyl-5- fluorouracil |